PGDM1400

Developed for: HIV infectious disease · acquired immunodeficiency · AIDS
Investigated by: National Institute of Allergy and Infectious Diseases (NIAID) · Beth Israel Deaconess Medical Center · Boris Juelg, MD PhD · Harvard School of Public Health (HSPH) · International AIDS Vaccine Initiative · Janssen Pharmaceuticals
+3 more
· Orlando Immunology Clinic · Ragon Institute of MGH, MIT and Harvard · University of Texas Health, Houston AIDS Research Team (HART)

2018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 12 trials · 1 met primary
Phase 1	NCT03928821	Jul 2019 → Mar 2021	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT03205917	Oct 2017 → Apr 2020	HIV infectious disease	International AIDS Vaccine Initiative	Completed	Met primary
Phase 1/21 trial
Phase 1/2	NCT04983030	Apr 2022 → Feb 2026	AIDS, acquired immunodeficiency	Boris Juelg, MD PhD	Completed	No outcome recorded
Comparator or background therapy1 trial
Phase 1/2	NCT03721510 Comparator	Dec 2018 → Oct 2021	HIV infectious disease	International AIDS Vaccine Initiative	Completed	No outcome recorded

Every value below carries the sentence it was read from. 4 sources stand behind the page.

Field	Value	Cited text
Known as	PGDM1400	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04983030 ↗ 3 NCT03928821 ↗ NCT03205917 ↗ NCT03721510 ↗
Modality	Monoclonal antibody	“PGDM1400, PGT121 and VRC07-523LS mAbs are recombinant human IgG1 monoclonal antibodies” NCT03205917 ↗
Route	Intravenous	“PGDM1400/Placebo (3mg/kg IV)” NCT03205917 ↗